The cause of TB is a slow-growing bacterium known as Mycobacterium tuberculosis. Scientists have known for some time that when host cells are invaded by this bacterium, the host cells are able to call up additional immune cells such as lymphocytes to fight them and try to limit the damage which the bacteria can cause.
The new research, by scientists from Imperial College London, the Universities of Cambridge and Oxford, and other international institutions, identifies a receptor on the host cells which triggers the immune cells’ response to tuberculosis. The scientists demonstrated that without this receptor, known as CCR5, mycobacteria were able to thrive inside host cells, as the immune cells did not receive the signal from CCR5 to attack them.
The scientists hope that their findings could enable a novel vaccine or immunotherapy to be developed which could artificially kick the immune cells into action in the same way as CCR5. This could boost the immune response to TB.
Both types of interventions are urgently required, since the BCG vaccine does not offer optimal protection and the current treatment regimens for tuberculosis require at least 6 months medication. This encourages the development of multi-drug resistant strains, as patients often do not complete the full course of treatment.
Dr Beate Kampmann, from the Wellcome Trust Centre for Clinical Tropical Medicine and the Department of Paediatrics at Imperial College London, and one of the authors of the study, said: “These results describe a novel mechanism whereby Mycobacterium tuberculosis communicates with the human immune system. Another piece of this complex jigsaw has been filled in, which will help us to target TB with very specific drugs or vaccines.
"We can now test potential vaccines or drug candidates for the desired effect, as we understand better how they should act," adds Dr Kampmann.
The scientists believe their research will also be of interest to those developing new drugs to combat HIV, which work by inhibiting the CCR5 receptor, which plays an important role in HIV-infection. The new research suggests that such drugs could impair the ability to fight off TB in HIV-infected patients receiving CCR5 receptor antagonists. TB is a big problem for individuals with HIV, as their weakened immune system renders them highly susceptible to this disease.
This research was funded by the Wellcome Trust, the UK Medical Research Council and the Swiss National Science Foundation. It was carried out by scientists from Imperial College London, UK; the University of Cambridge, UK; the University of Oxford, UK; National University of Singapore; Nanyang Technological University, Singapore; the University of Basel, Switzerland; and Lionex Diagnostics and Therapeutics GmbH, Germany.
Laura Gallagher | alfa
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy